Immunotherapy is improving the prognosis and survival of cancer patients, but despite encouraging out-comes in different cancers, the majority of tumors are resistant to it, and the immunotherapy combinations are often accompanied by severe side effects. Here, we show that a periodic fasting-mimicking diet (FMD) can act on the tumor microenvironment and increase the efficacy of immunotherapy (anti-PD-L1 and anti-OX40) against the poorly immunogenic triple-negative breast tumors (TNBCs) by expanding early exhausted effector T cells, switching the cancer metabolism from glycolytic to respiratory, and reducing collagen depo-sition. Furthermore, FMD reduces the occurrence of immune-related adverse events (irAEs) by preventing the hyperactivation of the immune response. These results indicate that FMD cycles have the potential to enhance the efficacy of anti-cancer immune responses, expand the portion of tumors sensitive to immuno-therapy, and reduce its side effects.

Cortellino, S., Raveane, A., Chiodoni, C., Delfanti, G., Pisati, F., Spagnolo, V., et al. (2022). Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. CELL REPORTS, 40(8), 111256 [10.1016/j.celrep.2022.111256].

Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects

Tripodo, Claudio;
2022-08-23

Abstract

Immunotherapy is improving the prognosis and survival of cancer patients, but despite encouraging out-comes in different cancers, the majority of tumors are resistant to it, and the immunotherapy combinations are often accompanied by severe side effects. Here, we show that a periodic fasting-mimicking diet (FMD) can act on the tumor microenvironment and increase the efficacy of immunotherapy (anti-PD-L1 and anti-OX40) against the poorly immunogenic triple-negative breast tumors (TNBCs) by expanding early exhausted effector T cells, switching the cancer metabolism from glycolytic to respiratory, and reducing collagen depo-sition. Furthermore, FMD reduces the occurrence of immune-related adverse events (irAEs) by preventing the hyperactivation of the immune response. These results indicate that FMD cycles have the potential to enhance the efficacy of anti-cancer immune responses, expand the portion of tumors sensitive to immuno-therapy, and reduce its side effects.
Settore MED/08 - Anatomia Patologica
Cortellino, S., Raveane, A., Chiodoni, C., Delfanti, G., Pisati, F., Spagnolo, V., et al. (2022). Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. CELL REPORTS, 40(8), 111256 [10.1016/j.celrep.2022.111256].
File in questo prodotto:
File Dimensione Formato  
Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 7.19 MB
Formato Adobe PDF
7.19 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/578965
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact